From: Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy
Clinical data | Total n = 79 (%) | Study 1 N = 30 (%) | Study 2 n = 49 (%) | |
---|---|---|---|---|
Gender | Men | 64 (81%) | 22 (73%) | 42 (86%) |
Women | 15 (19%) | 8 (27%) | 7 (14%) | |
Median age, yrs. (range) | 68 (35–82) | 68 (35–82) | 68 (48–80) | |
Stage | Locally advanced | 26 (33%) | 13 (43%) | 13 (27%) |
Metastatic | 53 (67%) | 17 (57%) | 36 (73%) | |
Treatmenta | Cisplatin + gemcitabine | 46 (59%) | 22 (76%) | 24 (49%) |
Carboplatin + gemcitabine | 9 (11%) | 6 (21%) | 3 (6%) | |
Vinflunine | 3 (4%) | 1 (3%) | 2 (4%) | |
Pembrolizumab | 20 (26%) | 0 (0%) | 20 (41%) | |
Admission to hospital | No | 32 (41%) | 10 (34%) | 22 (45%) |
Yes | 46 (59%) | 19 (66%) | 27 (55%) |